RCS - Hellenic Dynamics - New Company Presentation and Facility Presentation

Hellenic DynamicsAnnouncement

23/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231123:nRSW3918Ua&default-theme=true

RNS Number : 3918U  Hellenic Dynamics PLC  23 November 2023

23 November 2023

 

Hellenic Dynamics plc

("Hellenic Dynamics" or the "Company")

 

New Company Presentation and Facility Presentation

 

London, 23 November 2023, Hellenic Dynamics Plc (LSE: HELD), a medical
cannabis cultivator with a dedicated focus on producing tetrahydrocannabinol
("THC") dominant strains of medical cannabis flowers for the fast growing
European medical cannabis markets announces the publication of its new company
presentation and accompanying facility presentation.

 

Company Presentation

Hellenic is pleased to provide its updated company presentation which can be
accessed via the link 'Company Presentation
(https://www.dropbox.com/scl/fi/yw4z1iqaz8r727ijizt0e/Hellenic-Dynamics-Company-Presentation-November-2023-Final.pdf?rlkey=5eect38p259mgrj4fwew7rvl6&dl=0)
' and will be available on the Company's website by end of today.

 

Facility Presentation

Further to the announcement made on 10 October 2023, Hellenic is pleased to
provide its new facility presentation via the following link 'Facility
Presentation
(https://www.dropbox.com/scl/fi/pyw2zduhr40n6uwcynhfg/Hellenic-Dynamics-Facility-Presentation-November-23-V1.pdf?rlkey=da2k3xl4crkar4xbc0v8yazwg&dl=0)
' and will be available on the Company's website by end of today.

 

 

Enquires:

 

 Hellenic Dynamics plc               +44 (0) 20 3818 7850
 Davinder Rai                        davinder@hellenicdynamics.com

 Peterhouse Capital                  +44 (0)20 7469 0930
 Lucy Williams / Charles Goodfellow

 

About Hellenic Dynamics plc

 

Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation
and supply of THC ("tetrahydrocannabinol") - dominant strains of medical
cannabis flowers, destined for the growing medical cannabis markets
across Europe. Hellenic Dynamics' core strategy is to develop and operate its
40,000 square metre active cultivation licence from its 195,506 square metre
facility located near Thessaloniki in Northern Greece. In full production,
Hellenic Dynamics is capable of producing over 54,000 kg of dried flowers per
annum.

 

Hellenic Dynamics will take advantage of its relatively low cost base
resulting from a comparatively low cost of power, having its own running
water supply and the labour rates for skilled and semi-skilled labour in
Northern Greece.

 

26 European countries now allow medical cannabis via prescription and the
European cannabis market is expected to reach $17.39 billion per annum by
2028. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and
extracts are initially intended for export into Europe's largest market -
Germany, in addition to other European markets including domestically in
Greece.

 

As the first medical cannabis cultivator to obtain a listing on the main
market for listed securities of the London Stock Exchange, Hellenic is
significantly different to the number of CBD (Cannabidiol) related companies
that have appeared over the recent years. Hellenic Dynamics cultivates
THC-dominant medical cannabis flowers. THC-dominant medical cannabis products
are only available via a medical prescription. Medicinal cannabis has been
approved for use both in the United Kingdom and Germany, plus 24 other
European countries, for conditions including but not limited to chronic pain,
intractable chemotherapy-related nausea, anxiety, insomnia,
Tourette's syndrome, substance use disorder, multiple sclerosis, IBS, spinal
cord treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and
glaucoma.

For further information please visit our website www.hellenicdynamics.com
(http://www.hellenicdynamics.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGZMZMMZVGFZZ